进展期大肠癌患者术中应用化疗药物外周血CEA、CA19-9的检测及.PDF

® 2007 1 8 ; 15(1): 82-85 世界华人消化杂志 年 月 日 wcjd@ ISSN 1009-3079 CN 14-1260/R 临床经验 CLINICAL PRACTICE 进展期大肠癌患者术中应用化疗药物外周血C E A、 CA19-9的检测及临床意义 杨茂鹏, 于洪亮, 王夫景, 黄跃南, 杨维良 ■ 背景资料 杨茂鹏, 于洪亮, 王夫景, 黄跃南, 杨维良, 哈尔滨医科大学 P 0.01). CEA and CA19-9 levels were rapidly 大肠癌术后肝脏 第二临床附属医学院普外三科 黑龙江省哈尔滨市 150086 的转移是患者死 通讯作者: 王夫景, 150086, 黑龙江省哈尔滨市, 哈尔滨医科大 decreased in the patients received chemotherapy 亡的主要原因, 有 学第二临床附属医学院普外三科. (7 d post-operation: 7.96 ± 3.32 mg/L, 29.34 ± 关文献报道, 对于 yangmaopeng_yd2@163.com 11.05 kU/L, P 0.01 vs pre-operation), but they 电话: 0451 进展期大肠癌患 收稿日期: 2006-10-22 接受日期: 2006-11-02 were not significantly decreased in the patients 者, 即使行根治性 切除手术后, 肿瘤 without chemotherapy (7 d: post-operation: 复发和转移仍很 34.23 ± 20.59 mg/L, 88.12 ± 32.28 kU/L, P 0.05 常见, 大肠癌术后 Detection of serum vs pre-operation). 复发率达20% 左 carcinoembryonic antigen and 右. carbohydrate antigen 19-9 CONCLUSION: Detection of CEA and CA19-9 in patients with progressive in the peripheral blood confirms that portal vein colon cancer and its clinical continuous chemotherapy and great volume of significance intraperitoneal chemotherapy are effective in